Ionis Pharmaceuticals announced compelling late-stage data for Tryngolza, an RNA-targeting therapy, which significantly reduced triglyceride levels and acute pancreatitis incidences in patients with severe hypertriglyceridemia. These results could substantially expand Tryngolza’s market and therapeutic impact, positioning it as a major drug in lipid disorder management.